Financial Burden of Discarded Weight-based Antineoplastic Drugs to Payers and Patients in the Private Insurance Market

BACKGROUND: Our study estimated insurance payments and patient out-of-pocket (OOP) expenses associated with discarded weight-based intravenous antineoplastic drugs for privately insured US adult patients with cancer. METHODS: We identified patients who received weight-based antineoplastic drugs from...

Descripción completa

Detalles Bibliográficos
Autores principales: Shih, Ya-Chen Tina, Xu, Ying, Zhao, Hui, Schrag, Deborah, Yao, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8328094/
https://www.ncbi.nlm.nih.gov/pubmed/34350376
http://dx.doi.org/10.1093/jncics/pkab045

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8328094/
https://www.ncbi.nlm.nih.gov/pubmed/34350376
http://dx.doi.org/10.1093/jncics/pkab045

Ejemplares similares